Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management
Manuel Pabón-Carrasco,Alma Keco-Huerga,Manuel Castro-Fernández,Ilaria Maria Saracino,Giulia Fiorini,Dino Vaira,Ángeles Pérez-Aísa,Bojan Tepes,Laimas Jonaitis,Irina Voynovan,Alfredo J Lucendo,Ángel Lanas,Samuel J Martínez-Domínguez,Enrique Alfaro Almajano,Luis Rodrigo,Ludmila Vologzanina,Natasa Brglez Jurecic,Maja Denkovski,Luis Bujanda,Rustam A Abdulkhakov,Jose M Huguet,Luis Fernández-Salazar,Noelia Alcaide,Benito Velayos,Aiman Silkanovna Sarsenbaeva,Oleg Zaytsev,Tatiana Ilchishina,Jesús Barrio,Igor Bakulin,Monica Perona,Sergey Alekseenko,Marco Romano,Antonietta G Gravina,Óscar Núñez,Blas José Gómez Rodríguez,Diego Ledro-Cano,Rinaldo Pellicano,Pavel Bogomolov,Manuel Domínguez-Cajal,Pedro Almela,Judith Gomez-Camarero,Dmitry S Bordin,Antonio Gasbarrini,Juozas Kupčinskas,Anna Cano-Català,Leticia Moreira,Olga P Nyssen,Francis Mégraud,Colm O'Morain,Javier P Gisbert,Hp-EuReg Investigators,Javier Tejedor-Tejada,Galina Tarasova,Natalia Nikolaevna Dekhnich,Alfredo Di Leo,Giuseppe Losurdo,Miguel Fernández-Bermejo,Eduardo Iyo,Fernando Bermejo,Alicia Algaba,Ludmila Grigorieva,Luis Javier Lamuela Calvo,Itxaso Jiménez,Boris D Starostin,Natalia Baryshnikova,Luisa C de la Peña-Negro,Montserrat Planella,Consuelo Ramirez,Natalia V Bakanova,Fabio Farinati,Matteo Ghisa,Teresa Angueira,Alla Kononova,Ana Campillo,Ramón Pajares Villarroya,Barbara Gomez,Liya Nikolaevna Belousova,Debora Compare,Javier Alcedo,Diego Burgos-Santamaría,Francisco-José Rancel-Medina,Isabel Pérez-Martínez,Igor Maev,Dmitrii Andreev,Jesús M González-Santiago,José Xavier Segarra Ortega,Virginia Flores,Antonio Cuadrado-Lavín,Luis Hernández
DOI: https://doi.org/10.1002/ueg2.12476
Abstract:Background: Management of Helicobacter pylori (H. pylori) infection requires co-treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication. Aim: To evaluate the role of dosage of PPIs and the duration of therapy in the effectiveness of H. pylori eradication treatments based on the 'European Registry on Helicobacter pylori management' (Hp-EuReg). Methods: Hp-EuReg is a multicentre, prospective, non-interventionist, international registry on the routine clinical practice of H. pylori management by European gastroenterologists. All infected adult patients were systematically registered from 2013 to 2022. Results: Overall, 36,579 patients from five countries with more than 1000 patients were analysed. Optimal (≥90%) first-line-modified intention-to-treat effectiveness was achieved with the following treatments: (1) 14-day therapies with clarithromycin-amoxicillin-bismuth and metronidazole-tetracycline-bismuth, both independently of the PPI dose prescribed; (2) All 10-day (except 10-day standard triple therapy) and 14-day therapies with high-dose PPIs; and (3) 10-day quadruple therapies with clarithromycin-amoxicillin-bismuth, metronidazole-tetracycline-bismuth, and clarithromycin-amoxicillin-metronidazole (sequential), all with standard-dose PPIs. In first-line treatment, optimal effectiveness was obtained with high-dose PPIs in all 14-day treatments, in 10- and 14-day bismuth quadruple therapies and in 10-day sequential with standard-dose PPIs. Optimal second-line effectiveness was achieved with (1) metronidazole-tetracycline-bismuth quadruple therapy for 14- and 10 days with standard and high-dose PPIs, respectively; and (2) levofloxacin-amoxicillin triple therapy for 14 days with high-dose PPIs. None of the 7-day therapies in both treatment lines achieved optimal effectiveness. Conclusions: We recommend, in first-line treatment, the use of high-dose PPIs in 14-day triple therapy and in 10-or 14-day quadruple concomitant therapy in first-line treatment, while standard-dose PPIs would be sufficient in 10-day bismuth quadruple therapies. On the other hand, in second-line treatment, high-dose PPIs would be more beneficial in 14-day triple therapy with levofloxacin and amoxicillin or in 10-day bismuth quadruple therapy either as a three-in-one single capsule or in the traditional scheme.